Besancon University Hospital Center
Verified
Besançon, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying a condition known as vasoplegic syndrome, which can occur in patients undergoing heart surgery with the help of a machine that temporarily takes over the function of the heart and lungs, known as extracorporeal circulation. The study aims to compare two different treatments to manage blood pressure in these patients: Vasopressin and Norepinephrine. Vasopressin, also known by its code name REVERPLEG, is a medication that helps to increase blood pressure by narrowing blood vessels. Norepinephrine, also known as Noradrenaline, works similarly by tightening blood vessels to raise blood pressure.
The purpose of this study is to determine which of these two medications is more effective in preventing kidney problems and death within seven days after the onset of vasoplegic syndrome in patients undergoing heart surgery. Participants in the study will receive either Vasopressin or Norepinephrine through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.
The study will monitor participants for any kidney complications or other health issues for up to 90 days after the onset of vasoplegic syndrome. This includes checking for heart problems, digestive issues, and brain-related complications. The study will also look at the overall costs and effectiveness of the treatments, including how long patients stay in the hospital and the costs associated with their care. The goal is to find the best strategy to manage blood pressure and improve outcomes for patients at risk of kidney problems during heart surgery.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
19 criteria
4 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Besançon, France
Vandoeuvre Les Nancy, France
Amiens, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication used in this clinical trial to help manage blood pressure in patients undergoing heart surgery. It works by narrowing blood vessels, which helps increase blood pressure. This is important during surgery because maintaining stable blood pressure can reduce the risk of complications, such as kidney problems or even death, especially in patients who are at risk of low blood pressure.
is another medication being tested in this trial for its ability to manage blood pressure during heart surgery. Like vasopressin, norepinephrine helps to increase blood pressure by tightening blood vessels. This can be crucial for patients who might experience dangerously low blood pressure during surgery, as it helps ensure that vital organs, like the kidneys, receive enough blood and oxygen, potentially reducing the risk of complications.
Vasopressin is administered through an intravenous injection, which means it is given directly into a vein. It is currently being studied in clinical trials to assess its effectiveness compared to norepinephrine in managing blood pressure in patients with vasoplegic syndrome undergoing cardiac surgery. The main therapeutic use of vasopressin in this context is to help maintain stable blood pressure and reduce the risk of kidney complications and death. At the molecular level, vasopressin works by binding to receptors in blood vessels, causing them to constrict and increase blood pressure. It is classified as a vasopressor, a type of medication that raises blood pressure.
Norepinephrine is also administered intravenously, directly into a vein, and is being compared to vasopressin in clinical trials for its role in managing blood pressure in patients with vasoplegic syndrome during cardiac surgery. Its primary therapeutic indication is to stabilize blood pressure and minimize the risk of kidney issues and mortality. Norepinephrine acts at the molecular level by stimulating receptors in the heart and blood vessels, leading to increased heart rate and blood vessel constriction, which raises blood pressure. It is classified as a vasopressor, similar to vasopressin, used to elevate blood pressure.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.